FibroTest® and Fibroscan® performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 11, 2011, Pages 720-730

  Poynard, Thierry ^a   de Ledinghen, Victor ^b   Zarski, Jean Pierre ^c   Stanciu, Carol ^d   Munteanu, Mona ^e   Vergniol, Julien ^b   France, Julie ^f   Trifan, Anca ^d   Moussalli, Joseph ^a   Lebray, Pascal ^a   Thabut, Dominique ^a   Ratziu, Vlad ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c Clinique universitaire d'hépato gastroentérologie   (France)

^d GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e CHU de Grenoble ^*

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FIBROSIS; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; RIGIDITY; SPECTRUM; COMPARATIVE STUDY; ELASTOGRAPHY; MIDDLE AGED; PROSPECTIVE STUDY; REPRODUCIBILITY;

ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS;

EID: 83155181614     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.07.003     Document Type: Article

References (37)

1. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-1075.
2. Sebastiani G., Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006, 12:3682-3694.
3. Castera L., Pinzani M. Non-invasive assessment of liver fibrosis: are we ready?. Lancet 2010, 375:1419-1420.
4. Poynard T. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy. J Hepatol 2010, 54:586-587.
5. ®-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol 2008, 32:22-38.
6. ®, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350.
7. Friedrich-Rust M., Ong M.F., Martens S., Sarrazin C., Bojunga J., et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008, 134:960-974.
8. Castera L., Denis J., Babany G., Roudot-Thoraval F. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines?. J Hepatol 2007, 46:528-529.
9. La Haute Autorité de santé (HAS) in France-The HAS recommendations for the management of the chronic hepatitis C using non-invasive biomarkers. (Accessed August 2007). http://www.has-sante.%20fr/portail/display.jsp%3Fid=c_476486.
10. Poynard T., Ingiliz P., Elkrief L., Munteanu M., Lebray P., Morra R., et al. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS One 2008, 3:e3857.
11. Poynard T., Muntenau M., Morra R., Ngo Y., Imbert-Bismut F., Thabut D., et al. Methodological aspects for the interpretation of liver fibrosis non-invasive biomarkers: a 2008 update. Gastroenterol Clin Biol 2008, 32:8-21.
12. Poynard T., Halfon P., Castera L., Munteanu M., Imbert-Bismut F., Ratziu V., et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 2007, 53:1615-1622.
13. Lambert J., Halfon P., Penaranda G., Bedossa P., Cacoub P., Carrat F. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem 2008, 54:1372-1378.
14. Castéra L., Foucher J., Bernard P.H., Carvalho F., Allaix D., Merrouche W., et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010, 51:828-835.
15. Zheng M.H., Shi Ke-Qing, Fan Yu-Chen, Chen Y.P. Meta-analysis using individual participant data is the gold standard for diagnostic studies. Hepatology 2011, 53:1062. (Letter).
16. Riley R.D., Lambert P.C., Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010, 340:c221.
17. Pambrun E., Bouteloup V., Thieóbault R., Asselineau J., De Leódinghen V., Perez P. On the validity of meta-analyses: exhaustivity must be warranted, exclusion of duplicate patients too. J Clin Epidemiol 2010, 63:342-343.
18. Zarski, et al. Comparison of 10 blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. AASLD 2009, [Abstract 1635].
19. Sporea I., Sirli R., Deleanu A., Tudora A., Popescu A., Curescu M., Bota S. Liver stiffness measurements in patients with HBV vs HCV chronic hepatitis: a comparative study. World J Gastroenterol 2010, 16:4832-4837.
20. ®). BMC Gastroenterol 2010, 10:40.
21. ® measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 2007, 46:628-634.
22. Roulot D., Czernichow S., Le Clésiau H., Costes J.L., Vergnaud A.C., et al. Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome. J Hepatol 2008, 48:606-613.
23. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996, 24:289-293. The METAVIR Cooperative Study Group.
24. ® diagnostic value in chronic liver disease BMC. Gastroenterology 2007, 7:40.
25. Obuchowski N.A., Goske M.J., Applegate K.E. Assessing physicians' accuracy in diagnosing paediatric patients with acute abdominal pain: measuring accuracy for multiple diseases. Stat Med 2001, 20:3261-3278.
26. Piton A., Poynard T., Imbert-Bismut F., Khalil L., Delattre J., Pelissier E., et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology 1998, 27:1213-1219.
27. ®. A reappraisal at 7 years of age. BMC Gastroenterol 2011, 11:39.
28. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
29. Zhou X., Obuchowski N., McClish D. Statistical Methods in Diagnostic Medicine 2002, John Wiley & Sons.
30. Hintze J.L. NCSS 2007 User Guide. Number Cruncher Statistical Systems software 2007, NCSS, Kaysville, Utah.
31. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2009. ISBN 3-900051-07-0, URL http://www.r-project.org/.
32. Jacqueminet S., Lebray P., Morra R., Munteanu M., Devers L., Messous D., et al. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. Clin Gastroenterol Hepatol 2008, 6:828-831.
33. ®) in patients with chronic hepatitis C. Clin Chem 2006, 52:1887-1896.
34. Poynard T., Halfon P., Castera L., Charlotte F., Bail B.L., et al. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther 2007, 25:733-739.
35. Coco B., Oliveri F., Maina A.M., Ciccorossi P., Sacco R., Colombatto P., et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007, 14:360-369.
36. Ingiliz P., Chhay K.P., Munteanu M., Lebray P., Ngo Y., Roulot D., et al. Applicability and variability of liver stiffness measurements according to probe position. World J Gastroenterol 2009, 15:3398-3404.
37. Poynard T. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy. J Hepatol 2011, 54:586-587.